What is ConsortiEX?
ConsortiEX is a specialized provider of DSCSA Compliance and IV Workflow Management Systems, primarily serving health system and hospital pharmacies. Their core mission is to streamline adherence to the Drug Quality and Security Act, thereby enabling healthcare providers to enhance patient safety. With a client base exceeding 1,000 hospitals, ConsortiEX distinguishes itself through a unique compliance guarantee, covering any incurred fines. Their integrated software platform facilitates comprehensive management of pharmaceutical ordering, distribution, and tracking, offering a unified solution for complex pharmacy operations.
How much funding has ConsortiEX raised?
ConsortiEX has raised a total of $5.5M across 6 funding rounds:
Debt
$250K
Unspecified
$1M
Angel/Seed
$625K
Private Equity
$2.6M
Unspecified
$750K
Debt
$350K
Debt (2014): $250K with participation from Wisconsin Economic Development Corporation
Unspecified (2015): $1M led by Open Prairie Ventures
Angel/Seed (2015): $625K, investors not publicly disclosed
Private Equity (2016): $2.6M, investors not publicly disclosed
Unspecified (2016): $750K backed by Serra Ventures
Debt (2020): $350K with participation from PPP
Key Investors in ConsortiEX
Open Prairie Ventures
Open Prairie Ventures is a private equity firm focused on agriculture and rural America, also investing in technology-based ventures. They aim to enhance capital accessibility in underserved markets and foster collaborative partnerships with portfolio companies.
Serra Ventures
Serra Ventures is a venture capital firm specializing in early-stage technology startups, particularly in the AgTech sector. They support entrepreneurs and startups seeking investment to drive innovation in technology and agriculture.
Wisconsin Economic Development Corporation
The Wisconsin Economic Development Corporation (WEDC) is the state's primary engine for economic development, focused on advancing opportunities for businesses within Wisconsin through various initiatives and support programs.
What's next for ConsortiEX?
The substantial enterprise-level funding positions ConsortiEX for accelerated growth and market expansion. This strategic investment is likely to fuel further development of their DSCSA Compliance and IV Workflow Management Systems, potentially enhancing their AI capabilities and expanding their service offerings to a broader healthcare market. The company's focus on regulatory compliance and patient safety, coupled with a robust financial backing, suggests a strategic push to solidify its leadership in the health system pharmacy technology space. Future initiatives may include strategic partnerships and acquisitions to broaden their technological footprint and market reach.
See full ConsortiEX company page
